Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Ga

@article{Casali2015TimeTD,
  title={Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Ga},
  author={Paolo Giovanni Casali and Axel le Cesne and Andres Poveda Velasco and Dusan Kotasek and Piotr Z. Rutkowski and Peter Hohenberger and Elena Fumagalli and Ian Judson and Antoine Italiano and Hans A.J. Gelderblom and Antoine A. Adenis and Joerg Thomas Hartmann and Florence Duffaud and David Goldstein and J. M. Broto and Alessandro Gronchi and Angelo P Dei Tos and Sandrine Marr{\'e}aud and Winette T A van der Graaf and John R Zalcberg and Saskia Liti{\`e}re and J -Y Blay},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 36},
  pages={4276-83}
}
PURPOSE In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST). PATIENTS AND METHODS Patients were randomly assigned to 2 years of imatinib 400 mg daily or no further therapy after surgery. The primary end point was overall survival; relapse-free survival (RFS), relapse-free interval, and toxicity were secondary end points. In 2009, given the concurrent… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…